Gilead Sciences, Inc. (GILD) reported lower-than-expected first-quarter 2025 results. Adjusted earnings per share (EPS) of $1.81 missed the Zacks Consensus Estimate by a penny. In the year-ago quarter, the company reported a loss per share of$1.32. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Total revenues of $6.7 billion also missed the Zacks Consensus Estimate of$6.8 billion. Revenues were roughly flat year over year as lower Veklury (remdesivir) and oncology sales were offs ...